Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave (naltrexone SR / bupropion SR) New Drug Application (NDA).
URL: http://www.news-medical.net/news/20130109/Orexigen-reports-progress-with-FDA-on-faster-path-to-Contrave-NDA-resubmission.aspx
No comments:
Post a Comment